The question
Sermorelin's US regulatory history cannot be reduced to an undated “FDA approved” label. GEREF products had FDA approvals that were later withdrawn. FDA subsequently determined that the products had not been withdrawn from sale for safety or effectiveness reasons. These statements describe different regulatory questions. FDA's 2013 determination.
What GEREF was approved to do
The historical record describes two uses: evaluating the pituitary's ability to release growth hormone, and treating idiopathic growth hormone deficiency in children with growth failure. The corresponding initial approvals were in 1990 and 1997. The sponsor later discontinued the products and requested withdrawal of their applications; withdrawal of approval took effect June 18, 2009. Federal Register record.
Those indications matter when reading a modern claim. A specific pediatric treatment history is not evidence for every proposed adult use. An approval statement needs the product, intended population and indication to be useful. Without those details, a historically true sentence can leave a misleading impression.
What the 2013 finding actually addressed
On March 4, 2013, FDA published its determination about the reasons for withdrawal. The notice allowed for potential abbreviated applications referencing GEREF, provided other legal requirements were met. It did not announce a newly approved anti-aging treatment. FDA determination.
A withdrawal-reason finding should be read within that narrow purpose. It does not tell you that every preparation carrying the ingredient name has been evaluated. Nor should the word “withdrawn” alone be used as evidence that an ingredient was found dangerously unsafe. The underlying document supplies the distinction that the headline omits.
Why a compounded preparation is a separate question
FDA does not approve compounded drugs or verify their safety, effectiveness and quality before marketing. A compounded preparation therefore cannot borrow an approval simply from an older medicine's ingredient name. FDA on compounded drugs.
When examining a product claim, look for an identifiable finished product and its own regulatory record. A reference to GEREF can explain history, but it cannot do that identification work for a different preparation. Likewise, a pharmacy's involvement and a prescriber's involvement are not substitutes for a product approval record.
Three questions that keep the history clear
First, which exact product does the statement refer to? Second, what use was evaluated? Third, what date does the status describe? These questions help distinguish a historical approval, a withdrawal decision and the status of a preparation being discussed today.
This review of the record, checked September 24, 2026, does not establish a present FDA-approved sermorelin product for general wellness. Anyone assessing such a claim should request the specific approval and current labeling rather than infer them from the molecule's history.
Read what peptides are for the broader category.
Related reading
Continue with why tesamorelin’s approved indication matters.
Sources & further reading
Research context last reviewed September 24, 2026. Last updated October 6, 2026. Educational reading, not individual medical advice. How this article was prepared.
